BMJ Case Reports 2012; doi:10.1136/bcr.12.2011.5449
  • Novel treatment (new drug/intervention; established drug/procedure in new situation)

Topical dobesilate eye drops for ophthalmic primary pterygium

  1. Guillermo Giménez-Gallego3
  1. 1Research, Hospital Ramon y Cajal, Madrid, Spain
  2. 2Servicio de Oftalmología, Hospital de día Pío XII, Madrid, Madrid, Spain
  3. 3Qiimica de Proteinas, Centro de Investigaciones Biológicas, Madrid, Spain
  1. Correspondence to Professor Pedro Cuevas, pedro.cuevas{at}


Selective inhibition of fibroblast growth factor and vascular endothelial growth factor signalling pathways is effective in causing regression of pterygia. Prompt regression of fibrovascular mass and conjunctival angiogenesis was documented 2 weeks after topical administration of dobesilate eye drops twice daily. At 3-month follow-up, no recurrence was seen and no ocular irritation and burning were noted. The authors believe that this is the first known successful use of topical dobesilate in primary pterygium.


  • Competing interests None.

  • Patient consent Obtained.

Register for free content

The full text of all Editor's Choice articles and summaries of every article are free without registration

The full text of Images in ... articles are free to registered users

Only fellows can access the full text of case reports (apart from Editor's Choice) - become a fellow today, or encourage your institution to, so that together we can grow and develop this resource

Don't forget to sign up for content alerts so you keep up to date with all the case reports as they are published, and let us know what you think by commenting on the Editor's blog

Navigate This Article